Solid Biosciences prices 14.97M shares at $5.61 in private placement

Solid Biosciences (SLDB) entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $240M private placement, before deducting placement agent fees and offering expenses, which is expected to close on or about March 9, 2026, subject to the satisfaction of customary closing conditions. The private placement is being conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement. In the private placement, the Company is selling 14,973,257 shares of common stock at a price of $5.61 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 27,807,482 shares of common stock at a price of $5.609 per pre-funded warrant. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately, and will be exercisable until exercised in full.The private placement was anchored by existing and new investors, including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital, among others Leerink Partners and Citigroup are acting as joint lead placement agents for the financing. Cantor is acting as co-lead placement agent for the financing. Truist and H.C. Wainwright & Co. are acting as co-placement agents for the financing.